10x Genomics (TXG) Competitors $14.30 +1.20 (+9.16%) Closing price 04:00 PM EasternExtended Trading$14.19 -0.11 (-0.77%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TXG vs. ADPT, PACB, TWST, VCYT, VNT, RAL, MIR, ST, CAMT, and EYPTShould you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Adaptive Biotechnologies (ADPT), Pacific Biosciences of California (PACB), Twist Bioscience (TWST), Veracyte (VCYT), Vontier (VNT), Ralliant (RAL), Mirion Technologies (MIR), Sensata Technologies (ST), Camtek (CAMT), and Eyepoint Pharmaceuticals (EYPT). 10x Genomics vs. Its Competitors Adaptive Biotechnologies Pacific Biosciences of California Twist Bioscience Veracyte Vontier Ralliant Mirion Technologies Sensata Technologies Camtek Eyepoint Pharmaceuticals 10x Genomics (NASDAQ:TXG) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Does the media favor TXG or ADPT? In the previous week, Adaptive Biotechnologies had 1 more articles in the media than 10x Genomics. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 11 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.67 beat Adaptive Biotechnologies' score of 0.42 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, TXG or ADPT? Adaptive Biotechnologies has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.91-$182.63M-$0.70-20.43Adaptive Biotechnologies$205.22M9.65-$159.49M-$0.82-15.85 Which has more volatility & risk, TXG or ADPT? 10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Do analysts rate TXG or ADPT? 10x Genomics currently has a consensus price target of $13.54, suggesting a potential downside of 5.30%. Adaptive Biotechnologies has a consensus price target of $12.38, suggesting a potential downside of 4.81%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is TXG or ADPT more profitable? 10x Genomics has a net margin of -13.13% compared to Adaptive Biotechnologies' net margin of -59.07%. 10x Genomics' return on equity of -12.88% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Adaptive Biotechnologies -59.07%-60.93%-23.03% Do insiders and institutionals hold more shares of TXG or ADPT? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 9.4% of 10x Genomics shares are held by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Summary10x Genomics and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks. Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXG vs. The Competition Export to ExcelMetric10x GenomicsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78B$2.15B$5.82B$9.73BDividend YieldN/AN/A3.84%4.09%P/E Ratio-20.4338.6631.1525.96Price / Sales2.9113.84474.77122.97Price / CashN/A50.7737.1558.38Price / Book2.306.709.116.39Net Income-$182.63M-$63.67M$3.26B$265.56M7 Day Performance7.04%4.61%2.12%1.98%1 Month Performance10.08%3.25%5.13%1.33%1 Year Performance-35.73%27.99%31.25%21.15% 10x Genomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXG10x Genomics3.9007 of 5 stars$14.30+9.2%$13.54-5.3%-43.1%$1.78B$610.78M-20.431,240ADPTAdaptive Biotechnologies2.4692 of 5 stars$12.41-4.8%$12.38-0.3%+174.0%$1.89B$178.96M-15.13790Analyst RevisionPACBPacific Biosciences of California2.1532 of 5 stars$1.33+1.5%$1.90+42.9%-18.4%$399.49M$154.01M-0.58730TWSTTwist Bioscience4.1868 of 5 stars$28.02-0.4%$49.40+76.3%-40.0%$1.69B$312.97M-19.32990Positive NewsVCYTVeracyte2.8594 of 5 stars$30.07-0.5%$40.90+36.0%-7.0%$2.37B$445.76M91.12790News CoveragePositive NewsVNTVontier3.6957 of 5 stars$42.45+0.8%$47.14+11.1%+21.4%$6.23B$2.98B16.148,000Dividend AnnouncementAnalyst ForecastRALRalliantN/A$43.27-0.5%$56.80+31.3%N/A$4.88BN/A0.007,000Analyst UpgradeMIRMirion Technologies0.8447 of 5 stars$20.49-0.3%$22.25+8.6%+85.9%$4.79B$860.80M682.972,860Positive NewsSTSensata Technologies4.4851 of 5 stars$32.36+1.7%$34.64+7.0%-16.4%$4.71B$3.93B43.1519,000Positive NewsCAMTCamtek3.4537 of 5 stars$85.51+1.9%$96.10+12.4%-17.0%$3.90B$429.23M31.32400Positive NewsEYPTEyepoint Pharmaceuticals1.9518 of 5 stars$11.33+2.2%$25.38+124.0%+28.2%$780.94M$51.90M-4.23120Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Pacific Biosciences of California Alternatives Twist Bioscience Alternatives Veracyte Alternatives Vontier Alternatives Ralliant Alternatives Mirion Technologies Alternatives Sensata Technologies Alternatives Camtek Alternatives Eyepoint Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXG) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access